AIM-PA.TO
Aimia Inc.$22.00
Jun 02, 2026
Market cap
$1.76M
52w range
—
P / E
—
EPS
—
Volume
—
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on Aimia Inc.’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- AIM ImmunoTech Inc. (AIM) Discusses Ampligen's Potential Role in Addressing BundiBugyo Ebola Outbreak Transcriptseekingalpha.com·Jun 04, 2026
- AIM ImmunoTech Releases Virtual Investor ‘What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparednessglobenewswire.com·Jun 04, 2026
- AIM ImmunoTech Releases Virtual Investor ‘What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparednessglobenewswire.com·Jun 04, 2026
- The Hour-Long Project We Never Would've Startedetftrends.com·Jun 03, 2026
- Candor Technology Integrates with Freddie Mac's AIM Check API to Automate Income Calculationsglobenewswire.com·May 13, 2026
- Jersey Oil and Gas well placed to unlock value - brokerproactiveinvestors.co.uk·May 12, 2026
- AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceedsglobenewswire.com·May 08, 2026
- AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potentialglobenewswire.com·May 07, 2026
Peers
No peer list available for AIM-PA.TO.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|